Person:
Fernández Ruiz, Virginia Esperanza

Profile Picture
Name
Fernández Ruiz, Virginia Esperanza
publication.page.department
Universidad de Murcia. Departamento de Enfermería
Repository logoRepository logo

Filters

2023 - 20242
2
2
Reset filters

Settings

Subject: Bariatric surgery ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Open Access
    Plasma short-chain fatty acid changes after bariatric surgery in patients with severe obesity
    (Elsevier, 2023-01-31) Marıa Antonia, Martínez-Sánchez; Balaguer-Roman, Andrés; Fernández Ruiz, Virginia Esperanza; Almansa-Saura, Sonia; García-Zafra, Victoria; Ferrer Gómez, Mercedes; Frutos Bernal, María Dolores; Queipo-Ortuño, María I.; Ruiz Alcaraz, Antonio José; Nuñez-Sánchez, María A.; Ramos-Molina, Bruno; Bioquímica y Biología Molecular B e Inmunología; Facultad de Biología
    Background: Obesity has reached epidemic dimensions in recent decades. Bariatric surgery (BS) is one of the most effective interventions for weight loss and metabolic improvement in patients with obesity. Short-chain fatty acids (SCFA) are gut microbiota-derived metabolites with a key role in body weight control and insulin sensitivity. Although BS is known to induce significant changes in the gut microbiota composition, its impact on the circulating levels of certain metabolites produced by the gut microbiota such as SCFA remains poorly understood. Objective: To determine the impact of BS on the circulating SCFA levels in patients with severe obesity. Setting University hospital. Methods: An observational, prospective study was performed on 51 patients undergoing Roux-en-Y gastric bypass. Plasma samples were collected at baseline (1 day before surgery) and at 6 and 12 months after BS. Plasma SCFA levels were determined by liquid chromatography–mass spectrometry. Results: The results revealed significant changes in the circulating levels of SCFA after BS. A marked increase in propionate, butyrate, isobutyrate, and isovalerate levels and a decrease in acetate, valerate, hexanoate, and heptanoate levels were observed 12 months after BS. Furthermore, the changes in the levels of propionate, butyrate, and isobutyrate negatively correlated with changes in body mass index, while those of isobutyrate correlated negatively with changes in the homeostatic model assessment for insulin resistance index. Conclusion: These results suggest that propionate, butyrate, and isobutyrate levels could be related to weight loss and improved insulin sensitivity in patients with severe obesity after BS.
  • Thumbnail Image
    Publication
    Open Access
    The role of PCSK9 in metabolic dysfunction-associated steatotic liver disease and its impact on bariatric surgery outcomes
    (2024-07-01) Nuñez-Sánchez, María Ángeles; Balaguer-Román, Andrés; Martínez-Sánchez, María Antonia; Castellano-Castillo, Daniel; Ferrer Gómez, Mercedes; Manuel Martínez, Carlos; Dolores Frutos, María; Queipo-Ortuño, María Isabel; Cardona, Fernando; Ramos-Molina, Bruno; Fernández Ruiz, Virginia Esperanza; Enfermería
    Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely tied to obesity. The degree ranges from steatosis (MASL) and steatohepatitis (MASH) to liver cirrhosis. PCSK9 controls cholesterol and lipid particle transport to the liver. PCSK9 might interfere with the pathophysiology of MASLD and bariatric surgery (BS) outcomes of patients with MASLD. Objectives: Evaluate the relationship between serum and hepatic PCSK9 levels with the degree of MASLD and the metabolic outcome of BS. Setting: University Hospital, Spain. Methods: A total of 110 patients with obesity undergoing BS were classified according to liver histology as controls, MAS, and MASH. PCSK9 levels in serum were measured before and 6 months after BS using enzyme-linked immunosorbent assay. PCSK9 protein and mRNA levels in liver tissue were analyzed by immunohistochemistry and reverse transcriptase-polymerase chain reaction, respectively. Results: Hepatic PCSK9 protein levels were diminished in MASL and MASH compared with patients without MASLD and showed a strong negative association with MASLD severity scores. Liver PCSK9 mRNA was higher in MASH compared with controls and MASL and showed positive associations with MASLD severity scores. There were no differences in serum PCSK9 pre or postBS between the groups. Pre- and postsurgery serum PCSK9 positively correlated with cholesterol fold-changes and body mass index (BMI), cholesterol, and low-density lipoprotein -cholesterol fold-changes, respectively. PCSK9 fold-change positively correlated with BMI changes and was the sole variable explaining BMI fold changes in a regression model. Conclusions: PCSK9 mRNA and protein in the liver might be associated with the degree of MASLD. Serum PCSK9 may be associated with cholesterol and/or BMI fold changes. Serum changes of PCSK9 after BS could explain BMI loss outcome.
Ir a Estadísticas